Everybody loves previews, and this issue of CHEST provides a great one. Like the early silent movies, lung volume reduction surgery (LVRS) has proven effective in gaining an audience, but has limited mass-market appeal. We are entering a great new age of therapeutics, in which medicine will harness the fruits of scientific advances in physiology, biochemistry, and molecular biology to improve the quality of life for many patients. Among the diseases proven most recalcitrant to treatment has been COPD, which has increased in prevalence and mortality to the point at which it is expected to be the third-leading cause of death by 2020.1–2 Recent reviews3 have highlighted new medical options now available for COPD management, particularly enhanced bronchodilator therapy (long-acting βagonists and anticholinergics) and anti-inflammatory medications such as inhaled corticosteroids. Despite this improving therapeutic landscape, COPD remains a progressive degenerative disease, accompanied by declining functional status with enormous costs to the individual and society.